#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary hyperoxaluria Progressive multifocal leukoencephalopathy Autoimmune hepatitis B precursor type acute leukaemia Gastric cancer Rhabdoid tumour Synovial sarcoma metastatic Acute promyelocytic leukaemia Pulmonary alveolar haemorrhage Hereditary haemorrhagic telangiectasia Ataxia telangiectasia Osteochondrodysplasia Cystic fibrosis lung Fabry's disease Oropharyngeal cancer recurrent More trials…

    Learn about Rare Diseases

    Epidermolysis bullosa – Treatment Angiosarcoma – Diagnostics Paroxysmal nocturnal haemoglobinuria – Trials in Disease Primary mediastinal large B-cell lymphoma – Basic Information Prolymphocytic leukaemia – Diagnostics Pemphigus – Trials in Disease Malignant fibrous histiocytoma – Diagnostics Osteosarcoma metastatic – Trials in Disease Mucopolysaccharidosis III – Treatment Osteosarcoma metastatic More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxybutynin Rupatadine Rbl005.3 Tucatinib Bilastine Procarbazine Kbp-336 Ads-011 Nitric Oxide 177LU-PSMA-I&T Alectinib Urea Cebsulfase Alfa Ribitol Ganciclovir Mometasone Furoate Anhydrous Caffeine Voxelotor Asundexian Epinephrine More therapies…

    Learn about Your Condition

    Short-bowel syndrome Endotracheal intubation Triple negative breast cancer Primary amyloidosis Craniosynostosis Skin papilloma Cold type haemolytic anaemia Measles Chondrosarcoma Thromboangiitis obliterans Fracture infection Somatic symptom disorder Tetanus Transplant rejection Usher's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multiple sclerosis

  • Study Comparing CT-P53 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Cetirizine Dihydrochloride
    • Methylprednisolone
    Bulgaria Croatia Czechia Poland Romania Spain

  • Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Natalizumab
    • Tenofovir Alafenamide
    Norway

  • Study on the Safety and Effects of Ocrelizumab for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Ocrelizumab
    • Methylprednisolone
    Italy Poland

  • Study on the Effectiveness and Safety of Sodium Cromoglicate for Treating Fatigue in Multiple Sclerosis Patients

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Sodium Cromoglicate
    Spain

  • Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Ocrelizumab
    • Methylprednisolone
    Belgium Bulgaria Croatia Denmark France Hungary +8

  • Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing Multiple Sclerosis Starting Anti-CD20 Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    The Netherlands
Previous Page
1 … 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!